Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06529523
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-26
Brief Title:
Tislelizumab in People With Colorectal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
PD-1 Blockade in Mismatch-repair Deficient Colorectal Cancer in Nigeria
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria The researchers will also look at the safety of the study drug
All participants in this study will be treatment naïve they have not yet received treatment for their cancer and their cancer will be mismatch repair deficient dMMR dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process
All participants in this study will be treatment naïve they have not yet received treatment for their cancer and their cancer will be mismatch repair deficient dMMR dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None